Zai Lab (ZLAB) is back in focus after its second quarter 2026 earnings update, which showed revenue of US$106.31 million and a wider net loss, alongside fresh attention on newly approved products in China.

At a share price of US$23.57, Zai Lab has seen strong short term momentum, with a 7 day share price return of 29.65% and year to date share price return of 36.01%. The 1 year total shareholder return is still down 32%, which signals that recent enthusiasm after the Q2 update and new product approvals is emerging against a weaker longer term record.

If you are watching how sentiment can shift around earnings and approvals, it may be a good moment to look at other healthcare related opportunities through the 43 healthcare AI stocks.

After that sharp swing in Zai Lab’s share price, the gap between the current US$23.57 level, analyst targets near US$32 and modelled fair value estimates near US$94 raises a simple question: Which reference point are you really pricing in?

Most Popular Narrative: 29.2% Undervalued

Against the last close of $23.57, the most followed Zai Lab narrative anchors fair value near $33.30 and builds its case around future growth and margins.

The analysts have a consensus price target of $33.3 for Zai Lab based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $52.0, and the most bearish reporting a price target of just $21.6.

Curious what justifies that gap between today’s price and the fair value estimate? The narrative leans heavily on brisk revenue growth, margin improvement and a rich future earnings multiple. The exact mix of growth, profitability and discount rate assumptions might surprise you.

Result: Fair Value of $33.30 (UNDERVALUED)

However, Zai Lab’s reliance on in-licensed drugs and exposure to China pricing and reimbursement decisions could pressure margins and slow the revenue story behind that 29.2% discount.

Next Steps

With sentiment on Zai Lab split between concern about risks and optimism about rewards, it makes sense to review the data now and decide where you stand by checking the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Zai Lab?

If Zai Lab has your attention right now, this is a great moment to broaden your watchlist with other clear opportunities that fit different investing styles.

• Spot potential bargains early by reviewing companies that screen as high quality yet priced attractively through the 51 high quality undervalued stocks.
• Strengthen your income stream by checking out stocks that appear in the 9 dividend fortresses and may offer higher yields with staying power.
• Prioritise resilience by scanning companies that show up in the 83 resilient stocks with low risk scores and stand out for more stable risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.